Treatment of vulvovaginal candidiasis in pregnancy. A comparative study.
A carefully controlled comparative study showed miconazole nitrate 2% vaginal cream (Monistat) to be a highly effective agent in the treatment of vaginal candidiasis in pregnant subjects. Miconazole nitrate was significantly more effective than nystatin (Mycostatin) in the treatment of vaginal candidiasis in all three trimesters of pregnancy, and also more effective regardless of whether the candidal infection was primary or recurrent. Observations relating to the safety of this therapy during pregnancy were made and discussed.
D000208:Acute Disease; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007231:Infant, Newborn; D008297:Male; D008825:Miconazole / Q000009:adverse effects / Q000627:therapeutic use*; D009761:Nystatin / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011261:Pregnancy Trimester, First; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D012008:Recurrence
D007093:Imidazoles; D009761:Nystatin; D008825:Miconazole